Additionally, a Phase I clinical study (NCT03182816) demonstrated the safety and feasibility of treating patients with advanced relapsed/refractory non-small cell lung cancer (NSCLC) using epidermal growth factor receptor (EGFR) CAR-T cells produced by the piggyBac transposon system instead of viral systems (104). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.